Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Purple Innovation, Inc.PRPL · Entity 7764 | Chief Marketing Officer | June 20, 2024 | June 21, 2024 |
| TIVITY HEALTH, INC.TVTY · Entity 125776 | Division President, Nutrition | January 06, 2020 | January 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Purple Innovation, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,069 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 56,069 · Balance 56,069 F1: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number.
TIVITY HEALTH, INC.
Report date January 06, 2020 · Filed January 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,827 |
Reported balance
After 2020-01-06 transaction · row 1
1 source rowRow 1 · 2020-01-06 · Tax withholding · Disposed 14,001 · Balance 176,827 F1: Reflects 14,001 shares withheld to cover the payment of taxes following the vesting of 43,762 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 14,001 shares withheld to cover the payment of taxes following the vesting of 43,762 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUTRI SYSTEM INC /DE/
Report date March 08, 2019 · Filed March 11, 2019
Section 16 reporting ended · disclosed 2019-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2019-03-08 · Disposition to issuer · Disposed 241,992 · Balance 0 F1: This amount includes 10,202 shares of Issuer Common Stock subject to restricted stock awards that, subject to the terms of the Issuer's Amended and Restated 2008 Long-Term Incentive Plan, as amended (the "Plan") and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F2: This amount includes 21,368 shares of Issuer Common Stock subject to PRSUs that, subject to the terms of the Plan and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 41,934 |
Reported balance
After 2019-03-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2019-03-08 · Grant · Acquired 41,934 · Balance 41,934 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 35,066 |
Reported balance
After 2019-03-08 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2019-03-08 · Grant · Acquired 35,066 · Balance 35,066 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 5,554 |
Reported balance
After 2019-03-08 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2019-03-08 · Grant · Acquired 5,554 · Balance 5,554 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 6,042 |
Reported balance
After 2019-03-08 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2019-03-08 · Grant · Acquired 6,042 · Balance 6,042 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 12,518 |
Reported balance
After 2019-03-08 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2019-03-08 · Grant · Acquired 12,518 · Balance 12,518 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 20,202 |
Reported balance
After 2019-03-08 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2019-03-08 · Grant · Acquired 20,202 · Balance 20,202 F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. |
| Common StockSEC Table I · non-derivative | Direct | 19,924 |
Reported balance
After 2019-03-08 transaction · row 8
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 8 · 2019-03-08 · Grant · Acquired 19,924 · Balance 19,924 F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2020-02-11 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-08 · Disposition to issuer · Disposed 41,934 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.52 · Expires 2020-03-21 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-08 · Disposition to issuer · Disposed 35,066 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2021-03-20 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-08 · Disposition to issuer · Disposed 5,554 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.98 · Expires 2022-01-02 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-08 · Disposition to issuer · Disposed 6,042 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.94 · Expires 2023-01-04 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-03-08 · Disposition to issuer · Disposed 12,518 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-08 · Disposition to issuer · Disposed 20,202 · Balance 0 F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-03-08 · Disposition to issuer · Disposed 19,924 · Balance 0 F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount includes 10,202 shares of Issuer Common Stock subject to restricted stock awards that, subject to the terms of the Issuer's Amended and Restated 2008 Long-Term Incentive Plan, as amended (the "Plan") and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4.
F2: This amount includes 21,368 shares of Issuer Common Stock subject to PRSUs that, subject to the terms of the Plan and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4.
F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement);
F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock.
F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder.
F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value.
F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder.
F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2017 Filed Jun 9, 2017 14:42 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 5,554 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-17-038803 · doc4.xml · derivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,114 Underlying: Common Shares · 5,554 shares Expires 2021-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 14:42 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 5,554 | $49.58 | $275,369.54 |
DisclosureSEC source: 0001209191-17-038803 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,513 F1 · kind: Sale pursuant to a 10(b)5-1 plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.15 to $50.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 14:42 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 5,554 | $14.95 | $83,032.30 |
DisclosureSEC source: 0001209191-17-038803 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 16:06 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 6,043 | $0.00 Strike: $18.98 | $0.00 |
DisclosureSEC source: 0001209191-17-030283 · doc4.xml · derivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,668 Underlying: Common Shares · 6,043 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 16:06 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 6,043 | $50.68 | $306,255.61 |
DisclosureSEC source: 0001209191-17-030283 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,513 F1 · kind: Sale pursuant to a 10(b)5-1 plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $51.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2017 Filed May 5, 2017 16:06 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 6,043 | $18.98 | $114,696.14 |
DisclosureSEC source: 0001209191-17-030283 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 16:15 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 6,043 | $0.00 Strike: $18.98 | $0.00 |
DisclosureSEC source: 0001209191-17-026245 · doc4.xml · derivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,711 Underlying: Common Shares · 6,043 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 16:15 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 6,043 | $53.80 | $325,111.59 |
DisclosureSEC source: 0001209191-17-026245 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,513 F1 · kind: Sale pursuant to a 10(b)5-1 plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.60 to $54.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2017 Filed Apr 7, 2017 16:15 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 6,043 | $18.98 | $114,696.14 |
DisclosureSEC source: 0001209191-17-026245 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 17:02 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 1,150 | $53.55 | $61,582.50 |
DisclosureSEC source: 0001209191-17-022334 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,513 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 17:02 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 664 | $53.95 | $35,822.80 |
DisclosureSEC source: 0001209191-17-022334 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,663 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 6,260 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · derivative · entry 6 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,754 Underlying: Common Shares · 6,260 shares Expires 2023-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · derivative · entry 5 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,014 Underlying: Common Shares · 5,000 shares Expires 2020-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 6,260 | $48.65 | $304,547.12 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · nonDerivative · entry 4 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,327 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.250 to $48.975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 5,000 | $48.69 | $243,458.00 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · nonDerivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,587 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.250 to $48.975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 6,260 | $20.94 | $131,084.40 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:11 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 5,000 | $8.38 | $41,900.00 |
DisclosureSEC source: 0001209191-17-019829 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2017 Filed Jun 16, 2017 16:13 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon stock | 13,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040478 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,965 F1 · security: Restricted stock units were granted upon the achievement of certain specified performance goals and will vest, subject to continued employment, on December 31, 2017. Read SEC document |
| February 11, 2017 Filed Feb 14, 2017 16:13 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 3,428 | $34.85 | $119,465.80 |
DisclosureSEC source: 0001209191-17-010458 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,327 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 16:34 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 911 | $36.75 | $33,479.25 |
DisclosureSEC source: 0001209191-17-002659 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,755 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:18 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon stock | 10,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001195 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,666 F2 · shares: Restricted shares were granted on January 3, 2017. Shares vest over three years in equal installments on January 3rd of each year. Price per share on day of grant is $35.10. F2 · price: Restricted shares were granted on January 3, 2017. Shares vest over three years in equal installments on January 3rd of each year. Price per share on day of grant is $35.10. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 17:18 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 777 | $34.65 | $26,923.05 |
DisclosureSEC source: 0001209191-17-001195 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,982 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.